<DOC>
	<DOCNO>NCT00293072</DOCNO>
	<brief_summary>Lupus vasculitis autoimmune condition life threaten . In order treat condition toxic therapy cyclophosphamide steroid often require . These standard treatment associate significant side effect . Furthermore proportion patient respond conventional therapy . Newer safer therapy seek . Rituximab drug eliminate B cell blood . B cell one part human immune system help prevent infection . Abnormal activity immune system responsible autoimmune disease although exact mechanism lupus vasculitis yet establish . Rituximab liscenced treatment form B cell cancer call non-Hodgkins Lymphoma good safety track record use context . It recently use treat autoimmune condition positive result . In pilot study wish ass effectiveness safety rituximab patient lupus vascultis resistant conventional therpies .</brief_summary>
	<brief_title>Pilot Study Rituximab Therapy Systemic Lupus Erythematosus ( SLE ) Vasculitis</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Diagnosis SLE ANCA associate vasculitis 2 . Active disease refractory 6 month conventional therapy cyclophosphamide , prednisolone least one immunosupressive agent ( less period therapy tolerate ) 3 . Age 1870 1 . HbeAg HCV Ab positive know HIV positivity ( HIV test necessary study ) 2 . Pregnancy , inadequate contraception lactation 3 . Malignancy 4 . Current enrolment pother clinicla trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Rituximab , ANCA , vasculitis , lupus ,</keyword>
</DOC>